Carvana raises 2024 earnings guidance after topping Wall Street’s Q3 expectations

Carvana raises 2024 earnings guidance after topping Wall Street’s Q3 expectations


A Carvana sign and signature vending machine in Tempe, Arizona.

Michael Wayland | CNBC

Carvana on Wednesday raised its 2024 earnings guidance after the online used-car retailer significantly topped Wall Street’s third-quarter expectations.

Here’s how the company performed in the third quarter, compared with average estimates compiled by LSEG:

  • Earnings per share: 64 cents vs. 25 cents expected
  • Revenue: $3.65 billion vs. $3.45 billion expected

The company’s stock rose roughly 20% in after-hours trading Wednesday.

For 2024 guidance, Carvana said its adjusted earnings before interest, taxes, depreciation and amortization would be “significantly above the high end” of its previous target of $1 billion to $1.2 billion. The company reported $339 million in adjusted EBITDA last year.

Carvana’s new guidance signals expectations for a strong end of the year. The company said it expects a sequential increase in retail vehicle sales during the fourth quarter compared with the prior three months, which totaled 108,651 vehicles.

For the third quarter, the company’s net income was $148 million, down from $741 million a year earlier that was inflated by a gain on debt reduction. Adjusted EBITDA was $429 million and adjusted EBITDA margin was 11.7%, both topping company records achieved during the second quarter.

The company’s third-quarter 2023 results included adjusted EBITDA of $148 million and revenue of $2.77 billion.

Shares of Carvana are up roughly 300% this year as the company restructured operations and cut costs following Wall Street concerns of bankruptcy for the company in late 2022.

Carvana stock closed Wednesday at $207.31 per share, down less than 1%. Shares hit a new 52-week high earlier in the day of $213.98 per share.

Don’t miss these insights from CNBC PRO



Source

FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More
Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war
Business

Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war

Toyota Motor Corp. vehicles bound for shipment at the Port of Nagoya in Tokai, Aichi Prefecture, Japan, on Tuesday, April 29, 2025. Toru Hanai | Bloomberg | Getty Images DETROIT — Toyota Motor, Hyundai Motor and Chinese automakers such as Chery face the most potential impact of non-domestic automakers from the U.S.-Israel war with Iran, […]

Read More